2023-2027 Latin America Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-A 22-Country Analysis-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

September 2023 | | ID: 219164D68127EN
Venture Planning Group

Abstracts

The report is available in Local PDF, Global PDF, and Data Pack formats (supplier shares, test volumes, sales forecasts). The report is delivered in both Excel and PDF.This new 22-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.The report is available by section, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

• Oncogenes %li%Biochemical Markers %li%Growth Factors %li%Colony Stimulating Factors %li%Hormones %li%Immunohistochemical Stains %li%Lymphokines
• ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

• Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

• Assessment of latest technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies.
• Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

• Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
• The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Perkin Elmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others.Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

Contents

I. INTRODUCTION


II. WORLDWIDE MARKET OVERVIEW


III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS


V. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
 : :Abl/abl-bcr
 : :AIB1
 : :BCL-2
 : :BRCA1
 : :CD44
 : :C-fos
 : :C-myb
 : :C-myc
 : :CYP-17
 : :Erb-B
 : :HPC1
 : :N-myc
 : :P40
 : :P51
 : :P53
 : :PIK3CA
 : :PTI-1
 : :Ras
 : :Reg
 : :Sis
 : :Src and others
28. Polypeptide Growth Factors
 : :Basic Fibroblast Growth Factor
 : :Beta-TGF
 : :Cachectin (TNT)
 : :Calmodulin
 : :ECFR
 : :Nerve Growth Factor (NGF)
 : :Epidermal Growth Factor (EGF)
 : :Ornithine Decarboxylase
 : :Transferrin
 : :Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
 : :Alpha-Interferon
 : :B Cell Growth Factors
 : :B Cell Growth Factor (BCGF)
 : :Gamma-Interferon
 : :Interleukin-1 (IL-1)
 : :Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
 : :N-Acetylglucosamine
 : :Actin
 : :Alpha-Actin
 : :Antineuronal Antibodies
 : :7B2
 : :B72.3
 : :Bax
 : :BCD-F9
 : :BLCA-4
 : :Blood Group Antigens A,B,H
 : :CA
 : :CA 72-4/TAG-72
 : :CA
 : :CA-242
 : :CA-549
 : :CAM
 : :CAR-3
 : :Cathepsin-D
 : :Chromogranin A and B
 : :Cluster 1 Antigen
 : :Cluster-5/5A Antigen
 : :CTA
 : :CU18
 : :DR-70
 : :DU-PAN-2
 : :Endometrial Bleeding Associated Factor
 : :Endostatin
 : :Epithelial Membrane Antigen
 : :Feulgen Hydrolysis
 : :Fibronectin
 : :FSH
 : :(1-$$$$3)-L-fucosyltransferase
 : :Gastrin-Releasing Peptide (GRP)
 : :GDCFP-15
 : :Glucagon
 : :Glycoamines
 : :H23
 : :Her-2
 : :Human Carcinoma Antigen
 : :HPA
 : :HSP27
 : :Intermediate Filaments
 : :Cytokeratins/CK18/Cyfra 21-1
 : :Desmin
 : :Gliofibrillary Acid Protein
 : :Neurofilaments
 : :Vimentin
 : :KA
 : :Kinases
 : :KP16D3
 : :LAI
 : :Leukocyte Common Antigen
 : :Lewis Antigens
 : :Lysophosphatidic Acid (LPA)
 : :Ma 695/Ma
 : :MABDF3
 : :MAG
 : :ME1
 : :Minactivin
 : :MN/CA9
 : :MSA
 : :Mucin Cancer Antigen (MCA)
 : :Multiple Tumor Suppressor
 : :Myosin
 : :NEA-130
 : :NMP22
 : :OA-519
 : :Opioid Peptides
 : :P-glycoprotein
 : :Pancreatic Oncofetal Antigen (POA)
 : :Placental Lactogen
 : :PR92
 : :Proliferative Index, Ki-67
 : :Px
 : :RB Inactivation/Deletion
 : :Ret
 : :SCCL
 : :Selectin
 : :Sialic Acid
 : :Sialyl SSEA-1/SLX
 : :SN10
 : :Somatostatin
 : :TA-90
 : :TABA
 : :Tachykinin
 : :TAG
 : :TPS
 : :Troponin
 : :Tubulin
 : :VCAM
 : :VEGF
 : :Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing

VIII. 22-COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS, SUPPLIER SHARES


IX. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players
and start-up companies with innovative technologies and products, including:
 : :Abbott
 : :Affymetrix
 : :Beckman Coulter/Danaher/Cepheid
 : :Becton Dickinson
 : :bioMerieux
 : :Bio-Rad
 : :DiaSorin
 : :Eiken Chemical
 : :Elitech Group
 : :Enzo Biochem
 : :Fujifilm Wako
 : :Fujirebio
 : :Grifols
 : :Hologic
 : :Leica Biosystems
 : :PerkinElmer
 : :Qiagen
 : :QuidelOrtho
 : :Roche
 : :Siemens Healthineers
 : :Takara Bio
 : :Thermo Fisher and others.

List Of Tables

LIST OF TABLES

Argentina Cancer Diagnostic Volume Forecasts by Test
Argentina Cancer Diagnostics Sales Forecasts by Test
Bolivia Cancer Diagnostic Volume Forecasts by Test
Bolivia Cancer Diagnostics Sales Forecasts by Test
Brazil Cancer Diagnostic Volume Forecasts by Test
Brazil Cancer Diagnostics Sales Forecasts by Test
Chile Cancer Diagnostic Volume Forecasts by Test
Chile Cancer Diagnostics Sales Forecasts by Test
Colombia Cancer Diagnostic Volume Forecasts by Test
Colombia Cancer Diagnostics Sales Forecasts by Test
Costa Rica Cancer Diagnostic Volume Forecasts by Test
Costa Rica Cancer Diagnostics Sales Forecasts by Test
Cuba Cancer Diagnostic Volume Forecasts by Test
Cuba Cancer Diagnostics Sales Forecasts by Test
Dominican Republic Cancer Diagnostic Volume Forecasts by Test
Dominican Republic Cancer Diagnostics Sales Forecasts by Test
Ecuador Cancer Diagnostic Volume Forecasts by Test
Ecuador Cancer Diagnostics Sales Forecasts by Test
El Salvador Cancer Diagnostic Volume Forecasts by Test
El Salvador Cancer Diagnostics Sales Forecasts by Test
Guatemala Cancer Diagnostic Volume Forecasts by Test
Guatemala Cancer Diagnostics Sales Forecasts by Test
Haiti Cancer Diagnostic Volume Forecasts by Test
Haiti Cancer Diagnostics Sales Forecasts by Test
Honduras Cancer Diagnostic Volume Forecasts by Test
Honduras Cancer Diagnostics Sales Forecasts by Test
Jamaica Cancer Diagnostic Volume Forecasts by Test
Jamaica Cancer Diagnostics Sales Forecasts by Test

LIST OF TABLES

Mexico Cancer Diagnostic Volume Forecasts by Test
Mexico Cancer Diagnostics Sales Forecasts by Test
Nicaragua Cancer Diagnostic Volume Forecasts by Test
Nicaragua Cancer Diagnostics Sales Forecasts by Test
Panama Cancer Diagnostic Volume Forecasts by Test
Panama Cancer Diagnostics Sales Forecasts by Test
Paraguay Cancer Diagnostic Volume Forecasts by Test
Paraguay Cancer Diagnostics Sales Forecasts by Test
Peru Cancer Diagnostic Volume Forecasts by Test
Peru Cancer Diagnostics Sales Forecasts by Test
Puerto Rico Cancer Diagnostic Volume Forecasts by Test
Puerto Rico Cancer Diagnostics Sales Forecasts by Test
Uruguay Cancer Diagnostic Volume Forecasts by Test
Uruguay Cancer Diagnostics Sales Forecasts by Test
Venezuela Cancer Diagnostic Volume Forecasts by Test
Venezuela Cancer Diagnostics Sales Forecasts by Test
Tumor Marker Classification
Major Companies Developing or
Marketing ACTH Tests
Major Companies Developing or
Marketing AFP Tests
Major Companies Developing or
Marketing Beta-2 Microglobulin Tests
Major Companies Developing or
Marketing CA 15-3/27.29 Tests
Major Companies Developing or
Marketing CA 19-9 Tests
Major Companies Developing or
Marketing CA 125 Tests
Major Companies Developing or
Marketing Calcitonin Tests
Major Companies Developing or
Marketing CEA Tests
Major Companies Developing or
Marketing Estrogen Receptor Tests
Major Companies Developing or
Marketing Progesterone Receptor Tests
Major Companies Developing or
Marketing Ferritin Tests
Major Companies Developing or
Marketing Gastrin Tests
Major Companies Developing or
Marketing HCG Tests
Major Companies Developing or
Marketing Insulin Tests
Major Companies Developing or
Marketing NSE Tests
Major Companies Developing or
Marketing Occult Blood Tests
Major Companies Developing or
Marketing PAP Smear/HPV Tests
Major Companies Developing or
Marketing PAP Tests
Major Companies Developing or
Marketing PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or
Marketing Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications
in Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis